Abivax S.A.
23
2
4
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.7%
2 terminated/withdrawn out of 23 trials
88.9%
+2.3% vs industry average
13%
3 trials in Phase 3/4
50%
8 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
ABTECT - Maintenance
Role: lead
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Role: lead
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Role: lead
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Role: lead
Phase 1 Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation
Role: lead
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Role: lead
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Role: lead
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
Role: lead
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
Role: lead
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Role: lead
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
Role: lead
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
Role: lead
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
Role: lead
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Role: lead
ABX464 First in Man Study
Role: lead
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
Role: lead
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Role: lead
Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
Role: lead
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Role: lead
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Role: lead